---
schema_version: "secwatch.filing_event.v1"
accession: "0001842952-24-000083"
form_type: "8-K"
ticker: "CNTX"
cik: "0001842952"
company_name: "Context Therapeutics Inc."
filed_at: "2024-09-23T23:59:59+00:00"
generated_at: "2026-05-31T02:31:54.517657+00:00"
event_type: "m_and_a"
sentiment: "positive"
materiality_score: 0.7
calibrated_materiality_score: 0.7
confidence: "high"
source: SEC EDGAR
---

# Context Therapeutics licenses Nectin-4 x CD3 TCE bispecific from BioAtla for up to $133.5M

## Summary
- $15M upfront/near-term plus up to $118.5M milestones and tiered royalties on net sales.
- CT-202 (formerly BA3362) IND filing expected mid-2026; Context to fund all development.
- Cash runway into 2027 covering CTIM-76 and CT-95 Phase 1 trials plus CT-202 IND expenses.
- First CTIM-76 patient dosing expected Oct/Nov 2024; initial dose escalation data 1H 2026.
- CT-95 Phase 1 initial dose escalation data expected mid-2026.

## SEC filing metadata
- accession: 0001842952-24-000083
- form_type: 8-K
- ticker: CNTX
- cik: 0001842952
- company_name: Context Therapeutics Inc.
- filed_at: 2024-09-23T23:59:59+00:00
- event_type: m_and_a
- sentiment: positive
- materiality_score: 0.7
- calibrated_materiality_score: 0.7
- confidence: high
- sec_items: 1.01, 7.01, 8.01, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1842952/000184295224000083/0001842952-24-000083-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1842952/000184295224000083/cntx-20240923.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001842952-24-000083
- JSON: https://secwatch.observer/filing/0001842952-24-000083.json
- Plain text: https://secwatch.observer/filing/0001842952-24-000083.txt

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.